KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Cash (2017 - 2025)

Amneal Pharmaceuticals has reported Change in Cash over the past 9 years, most recently at $74.5 million for Q4 2025.

  • Quarterly results put Change in Cash at $74.5 million for Q4 2025, up 85.98% from a year ago — trailing twelve months through Dec 2025 was $194.5 million (up 907.19% YoY), and the annual figure for FY2025 was $194.5 million, up 907.19%.
  • Change in Cash for Q4 2025 was $74.5 million at Amneal Pharmaceuticals, down from $154.7 million in the prior quarter.
  • Over the last five years, Change in Cash for AMRX hit a ceiling of $154.7 million in Q3 2025 and a floor of -$172.7 million in Q2 2021.
  • Median Change in Cash over the past 5 years was -$2.1 million (2022), compared with a mean of -$1.7 million.
  • Biggest five-year swings in Change in Cash: plummeted 728.24% in 2023 and later soared 1045.0% in 2024.
  • Amneal Pharmaceuticals' Change in Cash stood at -$53.9 million in 2021, then decreased by 12.59% to -$60.7 million in 2022, then surged by 105.77% to $3.5 million in 2023, then soared by 1045.0% to $40.1 million in 2024, then soared by 85.98% to $74.5 million in 2025.
  • The last three reported values for Change in Cash were $74.5 million (Q4 2025), $154.7 million (Q3 2025), and $15.3 million (Q2 2025) per Business Quant data.